Leadership
The head of Chugai's new $200m venture capital fund talks to Scrip about its investment priorities.
The Swiss-headquartered, NASDAQ-listed group has posted a Phase II win for OCS-05 in acute optic neuritis, which opens up its potential in additional, and much larger, neuro-ophthalmic indications, CEO Riad Sherif tells Scrip.
The head of AI and automation in drug discovery at Merck KGaA’s life science business talked to Scrip about the company’s AI-powered platform that leverages a “gold mine” of proprietary R&D data, better in silico predictions and the next frontier of AI.
The Swiss giant’s blockbuster gene therapy is currently only administered intravenously into patients with spinal muscular atrophy under two years of age. Its intrathecal candidate, called OAV-101, has just passed a Phase III test which could expand its use in children and young adults.
Recent moves in the industry include C-suite changes at Arcutis Biotherapeutics, Kronos Bio and Akari Therapeutics, plus Amgen gets a new chief scientific officer.
Merck’s India head for process solutions and Aragen Bioscience’s CEO talk about an incubator set-up and AI-led drug discovery to enable India’s research ecosystem, US tariffs on China, ADC and GLP-1 development, funding path for Goldman Sachs-investee Aragen and more in this video interview
Adam Steensberg talked to Scrip about his firm’s vision for obesity treatment, Zealand’s independence from neighbor Novo Nordisk, and the hunt for a partner for its amylin candidate, petrelintide.
Sanofi's EVP, manufacturing and supply, Brendan O’Callaghan, tells Scrip how modular concept manufacturing at a new site in Singapore can drive efficiencies and minimize downtime, with technologies such as digital twins expected to further improve operational metrics.
The immunology company has used business development to bring in atopic dermatitis bispecific antibodies. J&J VP-immunodermatology disease area leader Liza O’Dowd talked to Scrip about the developments.
Founder Ken Mulvany has returned to the artificial intelligence drug discovery specialist determined to ensure it plays to its “foundational strengths.” The UK firm has therefore initiated a major restructuring plan, along with the intention to delist from Euronext Amsterdam.
The Dutch group has assembled an impressive syndicate which is betting that the first-in-class monoclonal antibody CIT-013 could be a transformative treatment for rheumatoid arthritis and hidradenitis suppurativa.
Former Roche CEO Bill Burns reflects on transforming Roche into a global leader in specialty care and oncology. Now, as he spearheads efforts to combat antibiotic resistance, Burns shares insights on industry evolution, the power of cultural change, and the urgent need for a new business model in antibiotics development.
Recent moves in the industry include C-suite changes at Moderna, Valerio Therapeutics and Ocugen, plus IDEAYA Biosciences acquires chief commercial officer from Gilead Sciences.
The Scrip Awards has been celebrating industry successes for 20 years now and the 2024 ceremony at the beautiful Raffles London at the OWO saw Novo Nordisk and Bill Burns taking home the top prizes.
The motive for the shocking murder of Brian Thompson in New York City was still unknown Wednesday afternoon.
CEO Christophe Bourdon talked to Scrip about the company’s revitalization as revenue grew 10% in the third quarter.
While most drug development in the multiple sclerosis space has focused just on relapse prevention, Immunic’s dual-acting therapy vidofludimus calcium also offers a novel approach for neurodegeneration, its CEO Daniel Vitt tells Scrip.
Martin Makary’s ties to a compounder and telehealth company offering compounded GLP-1s may concern the drug industry and raise questions about his fundamental beliefs in the FDA’s role regulating drug manufacturing.
The Swiss major’s chief medical officer tells Scrip about how “an R&D/commercial continuum” is helping to speed up innovation across the group.
The US FDA’s Peter Marks told the Jefferies meeting that the agency’s scientific leadership will be protected, and said it wants to do more to help the sector accelerate innovation.